FrancophonIA/ELRC3.0 huggingface dataset:
English: REKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled pen follitropin delta
Croatian: REKOVELLE 36 mikrograma/1,08 mL otopina za injekciju u napunjenoj brizgalici folitropin delta
English: Each pre-filled pen with multidose cartridge contains 36 micrograms of follitropin delta in 1.08 millilitre of solution.
Croatian: Jedna napunjena brizgalica s višedoznim uloškom sadrži 36 mikrograma folitropina delta u 1,08 mililitara otopine.
English: Each pre-filled pen with multidose cartridge contains 72 micrograms of follitropin delta in 2.16 millilitre of solution.
Croatian: Jedna napunjena brizgalica s višedoznim uloškom sadrži 72 mikrograma folitropina delta u 2,16 mililitara otopine.
English: • Pull off the outer needle cap.
Croatian: • Skinite vanjski zatvarač igle.
English: • Before using the pen for the first time, you need to remove air bubbles from the cartridge
Croatian: • Prije prvog korištenja brizgalice, morate ukloniti mjehuriće zraka iz uloška (priprema) kako biste primili točnu dozu lijeka.
English: Each pre-filled pen with multidose cartridge contains 12 micrograms of follitropin delta in 0.36 millilitre of solution.
Croatian: Jedna napunjena brizgalica s višedoznim uloškom sadrži 12 mikrograma folitropina delta u 0,36 mililitara otopine.
English: REKOVELLE 12 micrograms/0.36 mL solution for injection in a pre-filled pen follitropin delta
Croatian: REKOVELLE 12 mikrograma/0,36 mL otopina za injekciju u napunjenoj brizgalici folitropin delta
English: 1 multidose cartridge with 9 pen injection needles
Croatian: 1 višedozni uložak s 9 igala za brizgalicu za injekciju.
English: Step 2: • Pull off the pen cap.
Croatian: Korak 5: • Skinite vanjski zatvarač igle.
English: 1 multidose cartridge with 6 pen injection needles
Croatian: 1 višedozni uložak sa 6 igala za brizgalicu za injekciju.
English: It is available in packs of 1 cartridge and 6 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 uloška i 6 igala za brizgalicu za injekciju.
English: • Only prime your pen the first time you use it.
Croatian: • Brizgalicu treba pripremiti samo kod prvog korištenja.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each pre-filled multidose pen delivers 12 micrograms follitropin delta in 0.36 mL One mL of solution contains 33.3 micrograms of follitropin delta
Croatian: NAVOĐENJE DJELATNE(IH) TVARI Svaki višedozni uložak sadrži 12 mikrograma folitopina delta u 0,36 mL.
English: It is available in packs of 1 pre-filled pen and 6 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 napunjene brizgalice i 6 igala za brizgalicu za injekciju.
English: Ovulatory patients with polycystic ovaries have been included in clinical trials (see section 5.1).
Croatian: Bolesnice koje imaju ovulaciju i policistične jajnike bile su uključene u klinička ispitivanja
English: It is available in packs of 1 cartridge and 9 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 uloška i 9 igala za brizgalicu za injekciju.
English: • Dizziness
Croatian: Dijareja
English: It is available in packs of 1 pre-filled pen and 9 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 napunjene brizgalice i 9 igala za brizgalicu za injekciju.
English: Headache
Croatian: Umor
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 36 micrograms/1.08 mL solution for injection follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 36 mikrograma/1,08 mL otopina za injekciju folitropin delta
English: It is available in packs of 1 cartridge and 3 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 uloška i 3 igle za brizgalicu za injekciju.
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 12 micrograms/0.36 mL solution for injection follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 12 mikrograma/0,36 mL otopina za injekciju folitropin delta
English: 1 multidose cartridge with 3 pen injection needles
Croatian: 1 višedozni uložak s 3 igle za brizgalicu za injekciju.
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 72 micrograms/2.16 mL solution for injection follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 72 mikrograma/2,16 mL otopina za injekciju folitropin delta
English: • Wipe the skin of your injection site with an alcohol swab to clean it. Do not touch this area again before you give your injection.
Croatian: • Očistite mjesto injiciranja na koži pomoću jastučića natopljenog alkoholom.
English: It is available in packs of 1 pre-filled pen and 3 pen injection needles.
Croatian: Dostupna je u pakiranjima od 1 napunjene brizgalice i 3 igle za brizgalicu za injekciju.
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 36 micrograms/1.08 mL solution for injection in a pre-filled pen follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 36 mikrograma/1,08 mL otopina za injekciju u napunjenoj brizgalici folitropin delta
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 12 micrograms/0.36 mL solution for injection in a pre-filled pen follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 12 mikrograma/0,36 mL otopina za injekciju u napunjenoj brizgalici folitropin delta
English: Keep the cartidge in the REKOVELLE injection pen.
Croatian: Injicirajte si preostali lijek iz Vaše brizgalice.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/001
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/001
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/002
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/002
English: NAME OF THE MEDICINAL PRODUCT REKOVELLE 72 micrograms/2.16 mL solution for injection in a pre-filled pen follitropin delta
Croatian: Uputa o lijeku: Informacije za korisnika REKOVELLE 72 mikrograma/2,16 mL otopina za injekciju u napunjenoj brizgalici folitropin delta
English: Discard used needles immediately after injection.
Croatian: Odmah nakon injiciranja, zbrinite iskorištenu iglu.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/006
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/006
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/004
Croatian: BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/004
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/005
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/005
English: Reproductive system neoplasms
Croatian: Posljedični režim doziranja lijeka REKOVELLE
English: Step 9:
Croatian: Korak 6:
English: MARKETING AUTHORISATION NUMBER(S) EU/1/16/1150/003
Croatian: 12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/16/1150/003
English: Further information on Gilenya can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Gilenya.
Croatian: Više informacija o lijeku Gilenya nalazi se na internetskim stranicama Agencije: ema.europa.eu/medicines/human/EPAR/Gilenya.
English: Gilenya is available as capsules (0.25 mg and 0.5 mg).
Croatian: Lijek Gilenya dostupan je u obliku kapsula (0,25 mg i 0,5 mg).
English: The recommended dose for adults is one 0.5 mg capsule taken once a day by mouth, the recommended dose for children depends on body weight.
Croatian: Preporučena je doza za odrasle osobe jedna kapsula od 0,5 mg koja se uzima jedanput na dan kroz usta, dok preporučena doza za djecu ovisi o tjelesnoj težini.
English: The main measure of effectiveness in all the studies was based on the number of relapses the patients experienced each year.
Croatian: Glavno mjerilo učinkovitosti u svim ispitivanjima temeljilo se na godišnjem broju relapsa u bolesnika.
English: In addition, the Agency concluded that all patients should have their heart activity closely monitored after the first dose.
Croatian: Osim toga, Agencija je zaključila da nakon prve doze lijeka svim bolesnicima treba pomno nadzirati rad srca.
English: ‘Relapsing-remitting' means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).
Croatian: „Relapsno-remitirajuća bolest” znači da u bolesnika dolazi do izbijanja simptoma (relapsi) nakon kojih slijede razdoblja oporavka (remisije).
English: Women should not become pregnant while taking Gilenya and for two months after treatment has stopped.
Croatian: Žene ne smiju zatrudnjeti za vrijeme uzimanja lijeka Gilenya, kao ni dva mjeseca poslije završetka terapije.
English: What measures are being taken to ensure the safe and effective use of Gilenya?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Gilenya?
English: Other information about Gilenya
Croatian: Ostale informacije o lijeku Gilenya
English: Side effects reported with Gilenya are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Gilenya pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: Because Gilenya decreases the heart rate and can affect the heart's electrical activity and rhythm, the patient's blood pressure and heart activity is checked before starting treatment and during treatment, and also if Gilenya treatment is restarted after an interruption.
Croatian: Budući da Gilenya snižava srčanu frekvenciju i može utjecati na električnu aktivnost srca i srčani ritam, provjeravaju se krvni tlak i rad srca bolesnika prije početka i za vrijeme liječenja te u slučaju ponovnog uvođenja terapije lijekom Gilenya nakon prekida.
English: The pack will also include information on a registry to collect data on babies born to women treated with Gilenya, as well as a patient reminder card for patients or their carers with key safety information.
Croatian: Informativni paket također će sadržavati informacije o registru u okviru kojeg će se prikupljati podatci o bebama koje su rodile žene liječene lijekom Gilenya, kao i karticu s podsjetnikom za bolesnike ili njihove njegovatelje s ključnim sigurnosnim informacijama.
English: It must also ensure that all doctors who prescribe Gilenya receive an information pack containing important safety information, including a checklist of the risks with Gilenya and the situations where its use is not recommended.
Croatian: Tvrtka također mora zajamčiti da svi liječnici koji propisuju lijek Gilenya dobiju informativni paket koji sadržava važne sigurnosne informacije, uključujući kontrolni popis rizika pri primjeni lijeka Gilenya i situacija u kojima primjena lijeka nije preporučena.
English: Gilenya received a marketing authorisation valid throughout the EU on 17 March 2011.
Croatian: Lijek Gilenya dobio je odobrenje za stavljanje u promet koje je na snazi u Europskoj uniji od 17. ožujka
English: Gilenya contains the active substance fingolimod.
Croatian: Gilenya sadržava djelatnu tvar fingolimod.
English: The most serious side effects are infections, macular oedema (swelling in the central part of the retina at the back of the eye) and atrioventricular block (a type of heart rhythm disorder) at the start of treatment.
Croatian: Najozbiljnije nuspojave su infekcije, makularni edem (oticanje u središnjem dijelu mrežnice u stražnjem dijelu oka) i atrioventrikularni blok (vrsta poremećaja srčanog ritma) na početku liječenja.
English: What is Gilenya and what is it used for?
Croatian: Što je Gilenya i za što se primjenjuje?
English: Gilenya can only be obtained with a prescription and treatment should be started and supervised by a doctor experienced in multiple sclerosis.
Croatian: Lijek Gilenya izdaje se samo na liječnički recept, a liječenje mora započeti i nadzirati liječnik s iskustvom u liječenju multiple skleroze.
English: An overview of Gilenya and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Gilenya i zašto je odobren u EU-u
English: Details on the recommendations for monitoring patients are found in the summary of product characteristics.
Croatian: Pojedinosti o preporukama za praćenje bolesnika nalaze se u sažetku opisa svojstava lijeka.
English: In multiple sclerosis, the immune system (the body's defences) incorrectly attacks the protective sheath around the nerves in the brain and spinal cord.
Croatian: Kod multiple skleroze imunosni sustav (obrambeni sustav tijela) greškom napada zaštitni sloj oko živaca u mozgu i leđnoj moždini.
English: The Agency decided that Gilenya's benefits are greater than its risks and recommended that it be given marketing authorisation.
Croatian: Agencija je zaključila da koristi od lijeka Gilenya nadmašuju s njim povezane rizike te je preporučila davanje odobrenja za stavljanje lijeka u promet.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Gilenya have also been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Gilenya nalaze se također u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: What are the risks associated with Gilenya?
Croatian: Koji su rizici povezani s lijekom Gilenya?
English: As for all medicines, data on the use of Gilenya are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Gilenya kontinuirano se prate.
English: Why is Gilenya authorised in the EU?
Croatian: Zašto je lijek Gilenya odobren u EU-u?
English: Gilenya must also not be used in patients with certain diseases affecting the heart and blood vessels or in those who have had such diseases or problems with the blood supply to the brain.
Croatian: Gilenya se ne smije primjenjivati ni u bolesnika s određenim bolestima srca i krvnih žila ni u bolesnika koji su imali takve bolesti ili probleme s opskrbom mozga krvlju.
English: The European Medicines Agency concluded that there is clear evidence of the benefit of Gilenya in relapsing-remitting multiple sclerosis in both adults and children and noted that it had the benefit of being taken by mouth while most other medicines for this disease are given by injection.
Croatian: Europska agencija za lijekove zaključila je da postoje jasni dokazi o koristima lijeka Gilenya u liječenju relapsno-remitirajuće multiple skleroze u odraslih i u djece te je primijetila prednost uzimanja lijeka kroz usta, dok se većina drugih lijekova za liječenje ove bolesti primjenjuje injekcijom.
English: However, because of possible side effects, the Agency concluded that Gilenya should only be used in patients who have a real need for the medicine either because their disease has not improved with at least one other disease-modifying therapy or because it is severe and getting worse rapidly.
Croatian: Međutim, zbog mogućih nuspojava lijeka Agencija je zaključila da lijek Gilenya treba primjenjivati samo u bolesnika koji imaju stvarnu potrebu za lijekom zato što primjena barem jedne druge terapije za modificiranje tijeka bolesti nije dovela do poboljšanja stanja bolesti ili zato što im je stanje teško i naglo se pogoršava.
English: The checklist includes information on the tests and monitoring in patients before and during treatment with Gilenya.
Croatian: Kontrolni popis sadržava informacije o pretragama i praćenju bolesnika prije početka i za vrijeme liječenja lijekom Gilenya.
English: It does this by blocking the action of a receptor (target) on the T cells called the sphingosine-1phosphate receptor, which is involved in controlling the movement of these cells in the body.
Croatian: Ona inhibira djelovanje receptora (ciljnog mjesta) za sfingozin 1-fosfat u T-stanicama, koji sudjeluje u reguliranju kretanja tih stanica kroz tijelo.
English: Of patients given Gilenya, 14% (15 out of 107) experienced relapses compared with 54% (58 out of 107) of patients given interferon beta-1a.
Croatian: U 14 % (15 od 107) bolesnika liječenih lijekom Gilenya došlo je do relapsa u usporedbi s 54 % (58 od 107) bolesnika koji su primali interferon beta-1a.
English: Gilenya is a type of medicine known as a ‘disease-modifying therapy' that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells.
Croatian: Gilenya je vrsta lijeka koji modificira tijek bolesti, a primjenjuje se u liječenju odraslih osoba i djece starije od 10 godina s visoko aktivnom relapsno-remitirajućom multiplom sklerozom (RRMS), bolesti živaca pri kojoj upala uništava zaštitnu ovojnicu živčanih stanica.
English: Three main studies in adults and one main study in children have found that Gilenya was more effective than placebo (a dummy treatment) or interferon beta-1a (another medicine for treating multiple sclerosis) in patients with relapsing-remitting multiple sclerosis.
Croatian: U trima glavnim ispitivanjima kojima su bile obuhvaćene odrasle osobe i u jednom glavnom ispitivanju kojim su bila obuhvaćena djeca utvrđeno je da je lijek Gilenya učinkovitiji od placeba (prividnog liječenja) i interferona beta-1a (drugog lijeka za liječenje multiple skleroze) u bolesnika s relapsnoremitirajućom multiplom sklerozom.
English: Gilenya must not be used in patients at risk of infections due to a weakened immune system, patients with a severe infection or a long-term active infection such as hepatitis, and patients with cancer or severe liver problems.
Croatian: Lijek Gilenya ne smije se primjenjivati u bolesnika u kojih postoji rizik od infekcija zbog oslabljenog imunosnog sustava, bolesnika s teškom infekcijom ili dugotrajnom aktivnom infekcijom kao što je hepatitis te bolesnika oboljelih od raka ili s ozbiljnim problemima s jetrom.
English: The most common side effects with Gilenya (seen in more than 1 patient in 10) are flu, sinusitis (inflammation of the sinuses), headache, cough, diarrhoea, back pain and raised liver enzyme levels (a sign of liver problems).
Croatian: Najčešće su nuspojave lijeka Gilenya (zabilježene u više od 1 na 10 bolesnika) gripa, sinusitis (upala sinusa), glavobolja, kašalj, proljev, bol u leđima i povišene razine jetrenih enzima (znak problema s jetrom).
English: How is Gilenya used?
Croatian: Kako se Gilenya koristi?
English: The company that markets Gilenya will provide results from a study to assess the risk of side effects on the heart and circulation.
Croatian: Tvrtka koja stavlja lijek Gilenya u promet provest će ispitivanje kojim će procijeniti rizik od nuspojava povezanih sa srcem i cirkulacijom.
English: For more information about using Gilenya, see the package leaflet or contact your doctor or pharmacist.
Croatian: Više informacija o primjeni lijeka Gilenya pročitajte u uputi o lijeku, odnosno obratite se liječniku ili ljekarniku.
English: Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.
Croatian: Lijek Gilenya primjenjuje se kada je bolest aktivna unatoč odgovarajućoj primjeni barem jedne druge vrste terapije koja modificira tijek bolesti ili kada je bolest teška i brzo se pogoršava.
English: The active substance in Gilenya, fingolimod, prevents T cells (a type of white blood cell involved in the immune system) travelling from the lymph nodes towards the brain and spinal cord, thus limiting the damage they cause in multiple sclerosis.
Croatian: Djelatna tvar lijeka Gilenya, fingolimod, sprečava kretanje T-stanica (vrsta bijelih krvnih stanica koje su dio imunosnog sustava) iz limfnih čvorova prema mozgu i leđnoj moždini, čime se ograničava šteta koju prouzročuju u slučaju multiple skleroze.
English: Patients treated with Gilenya had around half the number of relapses compared with patients given placebo.
Croatian: U bolesnika liječenih lijekom Gilenya zabilježen je otprilike upola manji broj relapsa u odnosu na bolesnike koji su primali placebo.
English: How does Gilenya work?
Croatian: Kako djeluje Gilenya?
English: In two studies involving a total of 2,355 patients, Gilenya was compared with placebo over two years.
Croatian: U dvama ispitivanjima kojima je bilo obuhvaćeno ukupno 2 355 bolesnika liječenje lijekom Gilenya tijekom dvije godine uspoređeno je s placebom.
English: What benefits of Gilenya have been shown in studies?
Croatian: Koje su koristi od lijeka Gilenya utvrđene u ispitivanjima?
English: Patients receiving Gilenya had around half the number of relapses compared with patients given interferon beta-1a.
Croatian: U bolesnika koji su primali lijek Gilenya zabilježen je otprilike upola manji broj relapsa u odnosu na bolesnike koji su primali interferon beta-1a.
English: In a third study involving 1,292 patients, Gilenya was compared with interferon beta-1a over one year.
Croatian: U trećem ispitivanju, kojim je bilo obuhvaćeno 1 292 bolesnika, liječenje lijekom Gilenya tijekom jedne godine uspoređeno je s interferonom beta-1a.
English: In a study involving 215 children, Gilenya was compared with interferon beta-1a for up to 2 years.
Croatian: U ispitivanju kojim je bilo obuhvaćeno 215 djece, liječenje lijekom Gilenya u trajanju do dvije godine uspoređeno je s interferonom beta-1a.
English: For the full list of side effects of Gilenya, see the package leaflet.
Croatian: Potpuni popis nuspojava zabilježenih pri primjeni lijeka Gilenya potražite u uputi o lijeku.
English: The review of Esmya was initiated at the request of European Commission on 30 November 2017, under Article 20 of Regulation (EC) No 726/2004.
Croatian: Ocjenjivanje lijeka Esmya započeto je 30. studenoga 2017. na zahtjev Europske komisije, u skladu s člankom 20. Uredbe (EZ) br. 726/2004.
English: • Advise your patients about the signs and symptoms of liver injury.
Croatian: • Savjetujte bolesnice o znakovima i simptomima oštećenja jetre.
English: Healthcare professionals prescribing Esmya in the EU will receive a letter with further details.
Croatian: Zdravstveni radnici koji propisuju lijek Esmya u EU-u dobit će dopis s dodatnim pojedinostima.
English: On 8 February 2018, while the review was ongoing, the PRAC issue temporary recommendations.
Croatian: PRAC je 8. veljače 2018., tijekom postupka ocjenjivanja, izdao privremene preporuke.
English: If the tests indicate that you have a liver problem, your treatment will be stopped.
Croatian: Ako pretrage budu upućivale na to da imate problem s jetrom, vaše će se liječenje prekinuti.
English: The final stage of the review procedure is the adoption by the European Commission of a legally binding decision applicable in all EU Member States.
Croatian: U završnoj fazi postupka ocjenjivanja Europska komisija donosi pravno obvezujuće odluke koje se primjenjuju u svim državama članicama EU-a.
English: No new patients should start treatment for the time being
Croatian: Nove bolesnice zasad ne smiju započinjati s liječenjem.
English: 9 February 2018 EMA/152535/2018 - Corr. 1
Croatian: EMA/76828/2018
English: The PRAC's final recommendations will be forwarded to the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which will adopt an opinion.
Croatian: Konačne preporuke PRAC-a bit će proslijeđene Odboru za lijekove za humanu uporabu (CHMP), odgovornom za pitanja koja se odnose na lijekove za humanu uporabu, koji će donijeti mišljenje.
English: All women taking Esmya should have a liver function test at least once a month during treatment.
Croatian: Sve žene koje uzimaju lijek Esmya trebaju tijekom liječenja obavljati test jetrene funkcije barem jedanput mjesečno.
English: • If you have nausea (feeling sick), vomiting, upper belly pain, lack of appetite, tiredness or yellowing of the eyes or skin, contact your doctor immediately as these could be signs of liver problems.
Croatian: • U slučaju mučnine, povraćanja, boli u gornjem dijelu trbuha, gubitka apetita, umora ili žutila očiju ili kože odmah se obratite svojem liječniku jer to mogu biti znakovi problema s jetrom.
English: • If your treatment is stopped, your doctor will check how well your liver is working 2 to 4 weeks after you stop taking Esmya.
Croatian: • Ako se vaše liječenje prekine, liječnik će vam provjeriti rad jetre dva do četiri tjedna nakon što prestanete uzimati lijek Esmya.